Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $137.00. The company’s shares closed last Friday at $99.72. Don't ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a research note published on Friday, MarketBeat Ratings reports.

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish ...